Search

Displaying results 1511 - 1520 of 7452 in total
  1. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    indicated specifically for CDD. … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]

  2. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    [L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries … TrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

  3. Drug

    Metoprolol

    go.drugbank.com/drugs/DB00264
    ApprovedInvestigational

    Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.

    Categories: Antihypertensive Agents Indicated for Hypertension
  4. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.

    Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, BERIPLEX P/N 500 POWDER FOR SOLUTION FOR INJECTION
  5. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    age or weight. … [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  6. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed

  7. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    [A275508, A275509] On May 1, 2026, the FDA granted approval for vepdegestrant tablets under the trade name VEPPANU. … [A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies

  8. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 [A183062] for the treatment of narcolepsy with or without cataplexy. … FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063]

  9. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    The FDA has approved naltrexone for the treatment of alcohol dependence. … It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction.

    Categories: Heterocyclic Compounds with 4 or More Rings
  10. Drug

    Alvimopan

    go.drugbank.com/drugs/DB06274
    ApprovedInvestigational

    It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.

    Categories: Drugs for Constipation